Clinical Trials Logo

Encephalitis, Japanese clinical trials

View clinical trials related to Encephalitis, Japanese.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04817917 Active, not recruiting - Vaccine Reaction Clinical Trials

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

This study is to evaluate the seroprevalence of neutralizing antibodies against Japanese encephalitis (JE) virus in children aged 6 years who were previously administered with 5 different immunization strategies by JE attenuated live vaccine (JEV-L) or/and inactivated vaccine (JEV-I). The secondary objective is to evaluate the immunogenicity of the booster dose of JEV-I at 6 years old for those previously immunized with 3 doses of JEV-I or those sequential administered with 1 dose of JEV-L and another dose of JEV-I.

NCT ID: NCT04223037 Active, not recruiting - Clinical trials for Japanese Encephalitis Virus Disease

Purified Inactivated Japanese Encephalitis Vaccine

Start date: September 1, 2015
Phase: Phase 3
Study type: Interventional

This study evaluates the immunogenicity and safety of a purified inactivated JE vaccine compared to a commercialized JE vaccine. In this phase III, randomized, blind trial, infants at 6-23 months of age were randomly assigned to three groups to receive experimental vaccine or control vaccine with two different vaccination schedule respectively.

NCT ID: NCT01981967 Active, not recruiting - Clinical trials for Japanese Encephalitis

Post-licensure Safety Study of IMOJEV® in Thailand

Start date: November 2013
Phase: Phase 4
Study type: Interventional

The aim of this study is to further characterize the safety profile of IMOJEV®. Primary Objective: - To describe serious adverse events (SAEs, including adverse events of special interest [AESIs]) up to 60 days after administration of one dose of IMOJEV®. Secondary Objective: - To describe Grade 3 (severe) systemic Adverse Events (AEs) up to 30 minutes after administration of one dose of IMOJEV®.